Epidemiology of Klebsiella pneumoniae bloodstream infections in a teaching hospital: factors related to the carbapenem resistance and patient mortality by Lijun Tian et al.
RESEARCH Open Access
Epidemiology of Klebsiella pneumoniae
bloodstream infections in a teaching
hospital: factors related to the carbapenem
resistance and patient mortality
Lijun Tian1†, Ruoming Tan1†, Yang Chen1, Jingyong Sun2, Jialin Liu1, Hongping Qu1* and Xiaoli Wang1*
Abstract
Background: Although Klebsiella pneumoniae bloodstream infections (KP-BSIs) have recently attracted attention due
to an alarming raise in morbidity and mortality, there have been few reports on the epidemiology of KP-BSIs in
mainland China. We sought to describe the epidemiological, microbiological, and clinical characteristics of KP-BSIs,
focusing on the risk factors of carbapenem resistance and patient mortality.
Methods: A retrospective analysis of WHONET data of KP-BSI patients admitted to a teaching hospital in Shanghai,
China, between January 1, 2011 and December 31, 2015 was performed, and the annual percentage of patients
with carbapenem-resistant K. pneumoniae (CRKP) was determined. Risk factors related to the carbapenem resistance
and patient mortality were analyzed using binary logistic regression model. The genetic relatedness of CRKP strains
isolated from intensive care unit (ICU) patients was determined by pulsed-field gel electrophoresis (PFGE).
Results: A total of 293 incidences of KP-BSIs were identified in a 5-year period, 22.18% of these (65/293) were CRKP
strains, and the proportion of CRKP-BSI in ICU was 59.62% (31/52), equaling the levels observed in the epidemic
regions. A number of KP-BSIs (114), obtained from January 1, 2014, to December 31, 2015, were further investigated.
Skin and soft tissue infection source (odds ratio [OR] 26.63, 95% confidence interval [CI] 4.8–146.8) and ICU-acquired
infection (OR 5.82, 95% CI 2.0–17.2) was shown to be powerful risk factors leading to the development of CRKP-BSI.
The crude 28-day mortality rates of KP-BSI and CRKP-BSI patients were 22.8% and 33.3%, respectively. Lung as the
probable source of infection (OR 4.23, 95% CI 1.0–17.3), and high Sequential Organ Failure Assessment (SOFA) score
(OR 1.40, 95% CI 1.2–1.6) were strong prognostic factors determining crude 28-day KP-BSI mortality rates. PFGE
analysis demonstrated that 10/11 random CRKP isolates in ICU belonged to the same clonal type.
Conclusions: During the study period, we observed a significant increase in the occurrence of CRKP infections
among the identified KP-BSIs in our hospital and especially in ICU, and we demonstrated that carbapenem
resistance is associated with the increased mortality of KP-BSI patients.
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Background
Klebsiella pneumoniae (KP) is an important pathogen
responsible for severe diseases such as septicemia, pneu-
monia, urinary tract infections, and soft tissue infections,
and this pathogen is mainly associated with community-
and hospital-acquired infections [1]. Nielsen et al. re-
ported that K. pneumoniae is the second most common
cause of gram-negative bloodstream infections (BSIs),
after Escherichia coli, in adult population [2]. However,
the incidence of KP-BSIs had exceeded the incidence of
E. coli-caused BSIs in recent studies investigating inten-
sive care unit (ICU) patients [3, 4]. High mortality rates,
ranging from 20 to 40%, were reported for patients with
KP-BSI [5], but this incidence was reported to rise up to
67.6% for ICU patients [3].
Bacterial and host factors, as well as different treatment
regimens, most likely influence the outcomes of patients
with KP-BSI. Carbapenem-resistant K. pneumoniae
(CRKP) infections may be associated with an increased
rate of treatment failure and death [6], and the dramatic
increase in the occurrence of CRKP worldwide aggravates
this situation further [7]. Furthermore, older age, nosoco-
mial infections, intensive care interventions, disease sever-
ity, and several comorbidities were reported to represent
host factor contributing to the increased mortality rates of
KP-BSI patients [3, 5, 8, 9]. Additionally, β-lactams were
the first-line antibiotics selected for the treatment of KP-
BSI patients, however, with the increase in the number of
K. pneumoniae isolates producing extended-spectrum β-
lactamase, the use of carbapenems increased as well. More
importantly, CRKP isolates were shown to be resistant to
a variety of antibiotics, and to have the ability to hydrolyze
carbapenems, leaving few effective treatment options. The
use of combination therapy and appropriate empirical
treatment may provide useful prognostic information in
these patients [10–12].
Although the high mortality rates have been exten-
sively reported worldwide, to date, few studies have in-
vestigated the epidemiology of KP-BSIs in mainland
China. The aim of this study was to describe the epi-
demiological, microbiological, and clinical characteristics
of KP-BSIs in patients admitted to a teaching hospital in
Shanghai, China, focusing on the risk factors related to
carbapenem resistance and patient mortality.
Methods
Study design and population
Study design and all experimental procedures were ap-
proved by the Institutional Review Board of Ruijin Hos-
pital, an 1800-bed tertiary care university teaching
hospital in Shanghai, China. WHONET data provided by
clinical microbiology laboratory were used to identify all
KP-BSI patients between January 1, 2011, and December
31, 2015. Only the first KP-BSI reported for each patient
was included in our analyses. These data were used to
evaluate the rate of CRKP-BSIs.
We chose 114 incidences of KP-BSIs that occurred be-
tween January 1, 2014, and December 31, 2015 for fur-
ther investigation. Clinical and microbiological
characteristics and treatment outcomes were retrieved
from the medical records by two experienced ICU med-
ical doctors. The information about the patient demo-
graphics (age, gender), comorbidities (diabetes mellitus,
chronic renal failure, chronic liver disease, biliary tract
disease, congestive heart failure, chronic obstructive pul-
monary disease, malignancy, and immunosuppression),
probable source of infection, prior healthcare exposure
conditions, such as major surgery in the past 30 days
and the receipt of any antibiotic during >48 h in the past
30 days, was collected. Additionally, the general state of
patients on the onset of BSI was assessed, such as acute
kidney injury, septic shock, use of mechanical ven-
tilation, use of renal replacement therapy (RRT), and the
removal of the probable infectious source. Comorbid
conditions were also determined using the Charlson co-
morbidity index (CCI) as previously described [13], and
the severity of illness during the onset of BSI was calcu-
lated by the Pitt bacteraemia score (PBS) and Sequential
Organ Failure Assessment score (SOFA score) [14, 15].
Furthermore, the appropriate empirical antimicrobial
therapies described by Zarkotou were considered as well
[10]. We investigated attributable and crude in-hospital
mortality rates and 28-day mortality rates of patients, in
order to assess the treatment outcomes. Total length of
hospital stay (LOS) and LOS after BSI were evaluated,
while the primary outcome in this study was the crude
28-day mortality rate.
Definitions
BSI was defined according to the Centers for Disease
Control and Prevention guidelines (available at: http://
www.cdc.gov/nhsn/pdfs/pscmanual/17pscnosinfdef_cur-
rent.pdf). BSI onset was defined as the collection date of
isolate. Nosocomial infection was defined as an infection
that occurred more than 48 h after the admission of the
patient to the hospital or an infection that existed in pa-
tients who had been admitted to other hospitals in
2 weeks before the current admission [16]. ICU-
acquired BSI was defined as the first positive blood cul-
ture identified more than 2 days after ICU admission
(without a prior positive blood culture with the same
pathogen for at least 30 days). The probable infectious
source was determined on the basis of the microbio-
logical results and the analysis by 2 physicians. When no
source was identified, primary BSI was recorded. Appro-
priate empirical antimicrobial treatment refers to the ad-
ministration of in vitro active antimicrobials against the
study isolates, within ≤24 h from the BSI onset [10].
Tian et al. Antimicrobial Resistance and Infection Control  (2016) 5:48 Page 2 of 12
Septic shock was defined as sepsis associated with organ
dysfunction and persistent hypotension despite volume
replacement, and acute kidney injury (AKI) was defined
using the established criteria [17, 18]. Crude mortality
was defined as death occurring after the collection of the
first blood culture positive for K. pneumoniae. Mortality
attributable to BSI was defined by clinical evidence of
active infection and positive cultures, or when death oc-
curred as the result of organ failure that developed or
deteriorated during the onset of infection [19].
Microbiology
Vitek 2 automated system (bioMérieux, Marcy l’Etoile,
France) was used for isolate identification and antimicro-
bial susceptibility testing. Minimum inhibitory concen-
trations (MICs) were classified according to breakpoints
established by the Clinical and Laboratory Standards In-
stitute (CLSI2014) [20]. E. coli ATCC 25922 was used as
a quality control reference strain. The genetic related-
ness of CRKP strains obtained from ICU patients was
determined by pulsed-field gel electrophoresis (PFGE)
[21]. PFGE patterns were interpreted using the criteria
proposed by Tenover et al. [22].
Statistical analysis
All results are expressed as the mean ± standard deviation
(SD) or median (interquartile range [IQR]) (continuous
variables) or as percentages of the group from which they
were derived (categorical variables). Student’s t-test and
Mann-Whitney U-test were used to compare normally
and non-normally distributed continuous variables, re-
spectively. Categorical variables were compared using the
χ2 test or Fisher’s test, as appropriate. Odds ratios (ORs)
and 95% confidence intervals (CIs) were calculated for all
emerging associations. Multivariate analysis was used to
identify independent predictors by applying binary logistic
regression. Variables with p-value <0.05 in univariate test-
ing were incorporated into the model using a forward
stepwise approach, and p-value <0.05 was set as the limit
for the retention of the variables in the model. The good-
ness of fit for our logistic regression model was assessed
with Hosmer-Lemeshow test. In multivariate analysis, co-
morbidities were substituted using the CCI, and hospital
events on the onset of BSI were replaced by PBS and
SOFA score. Differences were considered to be significant
for p < 0.05. Data were analyzed with the IBM SPSS Statis-
tics for Windows (version 19.0). All susceptibility data
were analyzed using WHONET, version 5.6.
Results
Increased rates of CRKP-BSIs, especially among ICU
patients
KP-BSIs were collected and analyzed using WHONET
from January 1, 2011, to December 31, 2015 in our hos-
pital. During this period, 293 episodes of KP-BSI were
identified, and 22.18% (65/293) of these cases were
CRKP isolates, while 47.7% (31/65) of the CRKP isolates
were obtained from ICU. The annual rate of CRKP in
clinical isolates in China, obtained from the CHINET
surveillance of bacterial resistance [23], and the percent
of CRKP-BSI determined in this study are presented in
Fig. 1. The percentage of CRKP-BSIs in our hospital sig-
nificantly increased from 14.5% in 2012 to 29.8% in
2015, together with the percentage growth from 40% in
Fig. 1 CRKP among identified KP-BSIs from January 2011 to December 2015. Light grey bar, percentage of CRKP from CHINET; dark grey bar,
percentage of CRKP-BSI in Ruijin Hospital from WHONET; black bar, percentage of CRKP-BSI in ICU of Ruijin Hospital from WHONET
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2011 to 57.1% in 2015 in the isolates from ICU patients,
with the highest rate obtained in 2013, up to 80%. A
similar trend, with the rate of CRKP rising from 9.4% in
2011 to 15.6% in 2015 was observed in data obtained
from the CHINET surveillance program.
We demonstrated that the occurrence of CRKP strains
causing KP-BSIs since 2011 is increasing, and the annual
rates of these infections in the hospital included in this
study are much higher than the national average. Add-
itionally, the proportion of CRKP-BSIs in ICU patients
was 59.62% (31/52), which is significantly higher than
14.11% (34/241) of the patients with these infections in
non-ICU during this 5-year period (p < 0.001).
Risk factors associated with the development of CRKP-
BSIs
Because of the significant increase in the number of
CRKP-BSI cases in our hospital since 2014 and the in-
creased accuracy of the medical records, 114 incidences
of KP-BSIs that occurred between January 1, 2014, and
December 31, 2015, were further investigated. The mean
age of these 114 patients was 56 years (median: 67,
range: 12–90 years), and 64.9% (74/114) of the patients
were male. Most of the KP-BSIs (86.0%) were nosoco-
mial infections, and among them, 26 cases (22.8%) were
acquired at ICU. Most common infection sources were
primary bloodstream infections (23.7%), and intra-
abdominal (42.1%) and lung (14.0%) infections. The me-
dian CCI was 3 (IQR, 2-6) with the most frequent co-
morbidities being malignancy (51.8%), biliary tract
disease (30.7%), and diabetes mellitus (26.3%). The me-
dian PBS and SOFA score were 1 (IQR, 1–2.25) and 3
(IQR, 1–6), respectively.
To identify the clinical characteristics affecting the de-
velopment of CRKP-BSIs, we compared the clinical char-
acteristics of patients with CRKP-BSIs and CSKP-BSIs
(Table 1). The factors determined to be significantly asso-
ciated with CRKP-BSIs, using the univariate analysis, in-
cluded nosocomial infection, ICU-acquired infection,
probable infection source from skin and soft tissue, prior
exposure to antimicrobial therapy in the past 30 days, and
high PBS. In contrast, diabetes mellitus, malignancy, and
high CCI were common in patients with CSKP-BSIs.
Using multivariate analysis, skin and soft tissue infection
source (OR 26.63, 95%CI 4.8–146.8) and ICU-acquired in-
fection (OR 5.82, 95%CI 2.0–17.2) was determined to be
independent factors for CRKP-BSI development.
Comparison of antimicrobial therapies and treatment
outcomes between CRKP-BSI and CSKP-BSI patients
Antimicrobial therapies and outcomes of patients with
KP-BSIs are presented in Table 2. Patients with CSKP-
BSI were more likely to receive appropriate empirical
therapy than the patients with CRKP-BSI. Patients with
CRKP-BSI had longer total LOS compared with the pa-
tients with CSKP-BSI (median [IQR], 50 [28-83] vs. 24
[16.5-51], p < 0.001). The crude 28-day mortality and in-
hospital mortality of KP-BSI patients were 22.8% (26/
114) and 26.3% (30/114), respectively. Crude in-hospital
mortality was higher in patients with CRKP-BSIs than in
those with CSKP-BSIs (42.4% vs. 19.8%, respectively, p =
0.013), and this difference existed when crude 28-day
mortality was compared (33.3% vs. 18.5%, respectively,
p = 0.087). Additionally, attributable 28-day mortality
and in-hospital mortality of KP-BSI patients was
21.1% (24/114) and 24.6% (28/114), respectively. Simi-
larly, in CRKP-BSI patients, the attributable 28-day
mortality and in-hospital mortality were significantly
higher than in CSKP-BSI patients (33.3% vs. 16%,
p = 0.04; 42.4% vs. 24.6%, p = 0.005, respectively).
Identification of clinical and microbiological
characteristics associated with crude 28-day mortality
A comparison of clinical and microbiological character-
istics of the patients enrolled in this study is presented
in Table 3. We aimed to identify the risk factors associ-
ated with crude 28-day mortality of KP-BSI patients. In
the univariate analysis, ICU-acquired KP-BSI was deter-
mined to be a risk factor (OR 2.81, 95% CI 1.1–7.3) and,
when all comorbidities were analyzed, chronic liver dis-
ease (OR 3.71, 95% CI 1.3–10.3) and congestive heart
failure (OR 5.00, 95% CI 1.2–20.2) were shown to be risk
factors as well. Probable lung infection (OR 6.13, 95% CI
2.0–18.7) was the source of these bloodstream infections
more frequently in non-survivors than in survivors.
Moreover, mortality rate was affected by the events on
the onset of BSIs, such as acute kidney injury, septic
shock, RRT use, and use of mechanical ventilation. Add-
itionally, high SOFA score (median [IQR], 9 [4–13.5] vs.
2 [1–4], p < 0.001) and high PBS (median [IQR], 5 [2–7]
vs. 1 [1, 2], p < 0.001) were associated the crude 28-day
mortality in univariate analyses. There was no statistical
difference in hospital events prior to the onset of BSI be-
tween survivors and non-survivors. Obtained using
multivariate logistic regression analysis, significant risk
factors for crude 28-day mortality were lungs as prob-
able source of infection (OR 4.23, 95% CI 1.0–17.3), and
high SOFA score (OR 1.40, 95% CI 1.2–1.6), after adjust-
ing for other confounding variables.
PFGE analysis of random CRKP ICU isolates
To further determine the genetic relatedness of CRKP
strains in ICU, we randomly selected 11 CRKP ICU iso-
lates for PFGE analysis. The obtained results indicated
that these isolates belong to two different clonal types
(Fig. 2). The predominant clonal type was shown to be A-
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Table 1 Comparison of clinical characteristics between CRKP-BSI and CSKP-BSI patients
Variable Total (n = 114) n(%) CRKP (n = 33) n(%) CSKP (n = 81) n(%) Univariate analysis Multivariate analysis
OR(95% CI) p-value OR(95% CI) p-value
General variables
Male sex 74(64.9) 22(66.7) 52(64.2) 1.12(0.5-2.6) 0.802
Age,years, mean ± SD 56.37 ± 16.36 51.70 ± 16.26 58.27 ± 16.11 NA 0.051
Poly-microbial BSI 11(9.6) 6(18.2) 5(6.2) 3.38 (1.0–12.0) 0.076
Nosocomial infection 98(86.0) 33(100) 65(80.2) NA 0.005 - -
ICU acquired infection 26(22.8) 14(42.4) 12(14.8) 4.24(1.7–10.7) 0.001 5.82(2.0–17.2) 0.002
Comorbidities
Diabetes mellitus 30(26.3) 3(9.1) 27(33.3) 0.20(0.1–0.7) 0.008
Chronic renal failure 8(7.0) 3(9.1) 5(6.2) 1.52(0.3–6.8) 0.689
Chronic liver disease 20(17.5) 5(15.2) 15(18.5) 0.79(0.3–2.4) 0.668
Liver cirrhosis 11(9.6) 2(6.1) 9(11.1) 0.52(0.1–2.5) 0.506
Biliary tract disease 35(30.7) 9(27.3) 26(32.1) 0.79(0.3–1.9) 0.612
Congestive heart failure 9(7.9) 4(12.1) 5(6.2) 2.10(0.5–8.4) 0.280
Chronic obstructive
pulmonary disease
3(2.6) 1(3.0) 2(2.5) 1.23(0.1–14.1) 1
Malignancy 59(51.8) 12(36.4) 47(58.0) 0.41(0.2–1.0) 0.036
Immunosuppression 26(22.8) 10(30.3) 16(19.8) 1.77(0.7–4.4) 0.223
CCI,median (IQR) 3(2–6) 3(0–4) 4(2–6) NA 0.005 - -
Probable source of infection
Lung 16(14.0) 5(15.2) 11(13.6) 1.14(0.4–3.6) 0.776
Urinary 1(0.9) 0(0) 1(0.9) NA 1
Intra-abdominal 48(42.1) 12(36.4) 36(44.4) 0.71(0.3–1.6) 0.428
Liver abscess 6(5.3) 1(3.0) 5(6.2) 0.48(0.1–4.2) 0.671
Skin and soft tissue 12(10.5) 10(30.3) 2(2.5) 17.17(3.5–84.0) <0.001 26.63(4.8–146.8) <0.001
Catheter 10(8.8) 5(15.2) 5(6.2) 2.71(0.7–10.1) 0.150













Table 1 Comparison of clinical characteristics between CRKP-BSI and CSKP-BSI patients (Continued)




74(64.9) 30(90.9) 44(54.3) 8.41(2.4–29.8) <0.001 4.04(1.0–16.5) 0.052
Surgery a 62(54.4) 21(63.6) 41(50.6) 1.71(0.7–3.9) 0.206
Events on the onset of BSI
SOFA score,median (IQR) 3(1–6) 4(1–7) 3(1–5) NA 0.098
PBS,median (IQR) 1(1-2.25) 2(1–5) 1(0–2) NA <0.001 - -
ain the past 30 days prior to onset of BSI
SD, standard deviation, IQR interquartile range, OR odds ratio, CI confidence interval, ICU intensive care unit, BSI bloodstream infection, CRKP carbapenem-resistant Klebsiella pneumoniae, CSKP carbapenem-sensitive













type (10 isolates [90.9%], including A1-subtype [n = 9] and
A2-subtype [n = 1]).
Discussion
The increase in the morbidity and mortality of KP-BSIs
has attracted a lot of attention recently, together with
the worldwide spread of hypervirulent and multidrug-
resistant K. pneumoniae strains. To the best of our
knowledge, this is the largest 5-year epidemiological
study of KP-BSIs in mainland China to date. In China,
CHINET data showed that the rate of carbapenem re-
sistance of K. pneumoniae isolates rose slowly from 3.0%
in 2005 to 4.9% in 2009, but a rapid increase in the
number of CRKP isolates has been reported since 2010,
with the current national average as high as 15.6% [23].
Over the past 10 years, the rate of CRKP has also in-
creased dramatically worldwide [7], and in the areas of
high CRKP endemicity, such as the United States, Israel,
Italy, and Greece, the percentage of CRKP-BSI was
shown to be 18–68% [19, 24–26]. In agreement with
these results, we observed an increase in CRKP-BSI rates
in our hospital after 2011, and the obtained data shows
that these rates are significantly higher than the average
rates in China, especially among ICU patients, although
the rate of CRKP-BSIs in non-ICU patients increased, ris-
ing up to 20% since 2014. Noteworthy, the incidence of
CRKP-BSIs in our ICU was higher than 50%, which is
similar to the rates observed in the endemic areas [25, 27],
however, it may be possible that the analyses focused on
the patient vulnerability and disease severity, and several
patients were transferred from the endemic CRKP regions
of China, such as Zhejiang and Jiangxi provinces [28].
Clinical characteristics associated with CRKP-BSI pa-
tients in our study were similar to those reported by
other studies, with the exception of probable skin and
soft tissue infection source [19, 29, 30]. Jolie et al. re-
ported that patients with ≥20% total body surface area
burns show a higher risk of bacteremia [31], and Bang et
al. found that the patients with extensive flame burns
are prone to septicemia [32]. In our study,patients with
KP-BSIs, with the infection source from skin and soft
tissue, were accepted to the burn center of the hospital,
and all suffered from flame injuries. In 10 out of these
12 patients, burns were found on over 30% of total body
surface area, and they underwent surgeries, usually com-
prised of debridement and grafting, and most of them
received antibiotic therapies containing third or fourth
generation cephalosporins or carbapenems. A previous
9-year-long study confirmed that CRKP incidences in-
crease significantly in severe burn patients with late BSIs
[33]. Additionally, Cen et al. determined that the rate of
CRKP strains has increased in recent years, although
Pseudomonas aeruginosa and Acinetobacter baumannii
were more frequently detected gram-negative bacteria in
a Chinese burn ward [34]. This suggests that it is vital to
protect the integrity of skin and mucosal barriers in the
critically ill patients or the patients undergoing invasive
procedures, in order to prevent the development of
antibiotic-resistant bacterial infections. All necessary
contact precautions should be employed by hospital staff
caring for these high-risk patients.
Interestingly, CSKP-BSIs were especially common
among the patients with diabetes mellitus, which may be
related to hypermucoviscous K. pneumoniae (HVKP). Dia-
betes mellitus has been considered a significant risk factor
for HVKP, prevalent in the Asian Pacific Rim since the
1980s [35]. Our unpublished data showed a high rate of
HVKP isolates in our hospital, and the overwhelming ma-
jority of them were CSKP.
The crude 28-day mortality in KP-BSI patients was
shown to be 22.8%, which increased to 33.3% in CRKP-
BSI patients, similar to the rates obtained in both Chin-
ese and foreign studies [12, 25, 29, 36–38]. Further-
more, the mortality of CRKP-BSI patients was shown to
be higher than that of CSKP-BSI patients, which may
be a consequence of the infection with ST11 clone,
which is a dominant CRKP strain in China [28] with an
increased pathogenic potential and resistance to serum
killing [39, 40]. Additionally, due to the limited CRKP
treatment options, inappropriate empirical therapy may
Table 2 Comparison of antimicrobial therapies and treatment outcomes between CRKP-BSI and CSKP-BSI patients
Treatment and outcomes Total (n = 114) CRKP (n = 33) CSKP (n = 81) p-value
Appropriate empirical antimicrobial therapy 78(68.4) 9(27.3) 69(85.2) <0.001
LOS after BSI onset,Days, median (IQR) 18.5(9–31) 24(9.5–51) 15(8.5–28) 0.066
Total LOS,days, median (IQR) 31.5(19.75–62.75) 50(28–83) 24(16.5–51) 0.001
Mortality rate
Crude 28-day mortality n(%) 26(22.8) 11(33.3) 15(18.5) 0.087
Crude in-hospital mortality n(%) 30(26.3) 14(42.4) 16(19.8) 0.013
Attributable 28-day mortality n(%) 24(21.1) 11(33.3) 13(16.0) 0.04
Attributable in-hospital mortality n(%) 28(24.6) 14(42.4) 14(24.6) 0.005
IQR interquartile range, BSI bloodstream infection, CRKP carbapenem-resistant Klebsiella pneumoniae, CSKP carbapenem-sensitive Klebsiella pneumoniae, LOS
length of stay
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Table 3 Identification of clinical and microbiological characteristics associated with crude 28-day mortality
Variable Total (n = 114) n(%) Death (n = 26) n(%) Survivors (n = 88) n(%) Univariate analysis Multivariate analysis
OR(95% CI) p-value OR(95% CI) p-value
General variables
Male sex 74(64.9) 20(76.9) 54(61.4) 2.10(0.8–5.8) 0.144
Age,years, mean ± SD 56.37 ± 16.36 55.54 ± 16.10 56.61 ± 16.52 NA 0.770
Poly-microbial BSI 11(9.6) 3(11.5) 8(9.1) 1.30(0.3–5.3) 0.711
Nosocomial infection 98(86.0) 23(88.5) 75(85.2) 1.33(0.3–5.1) 1
ICU acquired infection 26(22.8) 10(38.5) 16(18.2) 2.81(1.1–7.3) 0.03 - -
Comorbidities
Diabetes mellitus 30(26.3) 4(15.4) 26(29.5) 0.43(0.1–1.4) 0.150
Chronic renal failure 8(7.0) 1(3.8) 7(8.0) 0.463(0.05–3.9) 0.680
Chronic liver disease 20(17.5) 9(34.6) 11(12.5) 3.71(1.3–10.3) 0.017
Liver cirrhosis 11(9.6) 5(19.2) 6(6.8) 3.25(0.9–11.7) 0.122
Biliary tract disease 35(30.7) 8(30.8) 27(30.7) 1.00(0.4–2.6) 1
Congestive heart failure 9(7.9) 5(19.2) 4(4.5) 5.00(1.2–20.2) 0.028
Chronic obstructive
pulmonary disease
3(2.6) 0(0) 3(3.4) NA 1
Malignancy 59(51.8) 11(42.3) 48(54.5) 0.61(0.3–1.5) 0.273
Immunosuppression 26(22.8) 6(23.1) 20(22.7) 1.02(0.4–2.9) 0.97
Charlson comorbidity
index, median (IQR)
3(2–6) 3(2–6.75) 3(1.25–6) NA 0.576
Probable source of infection
Lung 16(14.0) 9(34.6) 7(8.0) 6.13(2.0–18.7) 0.002 4.23(1.0–17.3) 0.045
Intra-abdominal 48(42.1) 9(34.6) 39(44.3) 0.67(0.3–1.7) 0.379
Skin and soft tissue 12(10.5) 4(15.4) 8(9.1) 1.82(0.5–6.6) 0.465
Catheter-related 10(8.8) 2(7.7) 8(9.1) 0.83(0.2–4.2) 1




74(64.9) 20(76.9) 54(61.4) 2.10(0.8–5.8) 0.144













Table 3 Identification of clinical and microbiological characteristics associated with crude 28-day mortality (Continued)
Events on the onset of BSI
Acute kidney injury 16(14.0) 12(46.2) 4(4.5) 18.00(5.1–63.8) <0.001
Use of renal replacement
therapy
8(7.0) 5(19.2) 3(3.4) 6.75(1.5–30.5) 0.015
Septic shock 28(24.6) 16(61.5) 12(13.6) 10.13(3.7–27.5) <0.001
Use of mechanical
ventilation
24(21.1) 15(57.7) 9(10.2) 11.97(4.2–33.9) <0.001
Removal of the infectious
source
33(28.9) 6(23.1) 27(30.7) 0.68(0.2–1.9) 0.453
SOFA score, median (IQR) 3(1–6) 9(4–13.5) 2(1–4) NA <0.001 1.40(1.2–1.6) <0.001
Pitt bacteraemia score,
median (IQR)
1(1–2.25) 5(2–7) 1(1–2) NA <0.001 - -
CRKP 33(28.9) 11(42.3) 22(25.0) 2.20(0.9–5.5) 0.087
Appropriate empirical therapy 78(68.4) 14(53.8) 64(72.7) 0.44(0.2–1.1) 0.069
ain the past 30 days prior to onset of BSI
SD standard deviation, IQR interquartile range, OR odds ratio, CI confidence interval, ICU intensive care unit, BSI bloodstream infection, CRKP carbapenem-resistant Klebsiella pneumoniae, CSKP carbapenem-sensitive













contribute to their deleterious outcomes [4, 19]. Ac-
cording to the recent clinical observations, the treat-
ment of CRKP infections by a combination therapy
may result in the reduced mortality compared with
monotherapy [11, 12], but the treatment should be fur-
ther optimized.
To further investigate the risk factors associated with
crude 28-day mortality, we evaluated the influence of pa-
tient characteristics, K. pneumoniae isolates, and the
therapeutic interventions on KP-BSIs. After adjusting for
multiple confounders, several parameters, such as prob-
able source of infection from lung and high SOFA score,
were associated with a higher crude 28-day mortality, as
previously described [9, 41, 42]. For patients with SOFA
scores above 7 at the onset of bacteremia, the 14-day
mortality rate was shown to increase [43]. Here, a me-
dian SOFA score at the onset of CRKP-BSI was 9.
Therefore, SOFA score determined at the onset of BSI
may capture the risk associated with the severity of BSI
or the clinical impact of any other condition. It may help
physicians identify the patients with BSIs who have a
higher risk of in-hospital death. No significant difference
was observed between the inappropriate empirical ther-
apy and mortality, however, carbapenem resistance was
not found to be an independent predictor of mortality,
as previously reported [44], but such trend was ob-
served, which may be explained by a relatively small
sample population included in this study.
Increasing antibiotic resistance in ICUs represents a
major clinical concern, and we showed here that almost
half of all CRKP isolates were obtained from ICU pa-
tients, while further analysis showed that CRKP-BSIs are
associated with ICU acquired infection, which may lead
to higher mortality rates (38.5%). Different risk factors
for BSI development may affect patients in ICUs, includ-
ing the higher disease severity, disruption of anatomical
barriers, and impaired immunological response [45],
which may lead to the increase in the length of hospital
stay, worse outcomes, and the difficulties in the treat-
ment [46, 47]. Furthermore, we analyzed the genetic
relatedness of CRKP strains isolated from ICU pa-
tients, showing that the randomly isolated CRKP
strains are almost identical, which may result from a
nosocomial clonal expansion. It is worth noting that
the highest rate of CRKP-BSIs in ICU rose up to 80%
in 2013, but later, this percentage apparently de-
creased, most likely because of an integrated steward-
ship prevention study that was conducted in our ICU
from February 1, 2014, to August 31, 2015. In this
period, infection-control measures, such as active sur-
veillance culture, isolation precautions, enhanced con-
tact precautions, disinfection, and sterilization were
applied. Therefore, prompt and appropriate infection
control should be implemented upon the admission
of high-risk patients, especially in ICU.
Our study has several limitations. The extended
spectrum ß lactamase-producing K. pneumoniae strains
represent a major issue when analyzing multidrug-
resistant K. pneumoniae, however, we have not dis-
cussed this in our study. Clinical data were obtained
retrospectively from medical records, and therefore,
some differences in physician practices or accuracy of
information may exist. Additionally, the data for pa-
tients who may have had significant BSI symptoms such
as septic shock and hyperpyrexia, but were not tested
due to the patient refusal or because their blood culture
was negative, were not included. Finally, this was a
single-center study, including 114 patients with detailed
clinical analysis, and further multi-centric, prospective
studies are needed to confirm our findings and to assist
physicians in adopting more effective approaches for
KP-BSI treatment.
Fig. 2 PFGE analysis of random CRKP ICU isolates. Genomic DNA was digested using XbaI enzyme and subjected to PFGE. PFGE patterns were
interpreted by using the criteria proposed by Tenover et al. [24]. Lane M, a Salmonella serotype Braenderup strain (H9812) was used to normalize
migration variation occurring across the gel and to accurately determine sample band sizes
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Conclusions
A significant increase in the occurrence of CRKP among
the identified KP-BSIs in our hospital was observed, es-
pecially in ICU since 2011. We demonstrated that skin
and soft tissue infection source and ICU-acquired infec-
tion represent strong risk factors for CRKP-BSI develop-
ment. Probable lung infection source and high SOFA
score were independent predictors for crude 28-day
mortality of KP-BSI patients. Taken together, our results
clearly demonstrated that CRKP-BSIs are associated with
high morbidity and mortality, and clone spread may
contribute to the nosocomial dissemination of CRKP, re-
quiring the implementation of appropriate infection con-
trol, especially in ICU.
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